Forty Seven Stock
Clinical-stage immuno-oncology company
Sign up today and learn more about Forty Seven Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Forty Seven Stock
With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity.
Investors
GV
Uber, Robinhood, Jet, Impossible Foods, Lacework, Slack, Snyk, SambaNova Systems, DocuSign, Gusto
Lightspeed Venture Partners
Snap, OYO, AppDynamics, TripActions, Faire, Affirm, Netskope, LivingSocial, Weee!, ThoughtSpot
Sutter Hill Ventures
Lacework, Pure Storage, Sila Nanotechnologies, SiFive, Sumo Logic, Sigma Computing, Demandbase, C3 IoT, Menlo Security, Glassdoor
Funding History
| February 2016 | $75.0M |
|---|
Management
Cofounder
Irving Weissman
Press
WSJ - Feb, 24 2016
Venture Capitalists Invest $75M to Launch Forty SevenEquityZen Recognized As:
